Oncolytic initiation reduces medication adherence for comorbid chronic conditions
Treatment with oral oncolytics may negatively affect adherence to oral therapies for chronic comorbid conditions among patients with chronic myeloid leukaemia, chronic lymphocytic leukaemia/small lymphocytic lymphoma, or multiple myeloma, reveals a study.